Soligenix (NASDAQ:SNGX – Get Free Report) issued its earnings results on Friday. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.05, Zacks reports.
Soligenix Price Performance
Shares of NASDAQ SNGX opened at $1.37 on Friday. The firm has a market cap of $5.87 million, a price-to-earnings ratio of -0.36 and a beta of 2.00. The stock’s fifty day moving average price is $1.94 and its two-hundred day moving average price is $1.99. Soligenix has a one year low of $1.09 and a one year high of $6.23.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the company. Alliance Global Partners lowered their price target on Soligenix from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, July 16th. Wall Street Zen cut Soligenix to a “strong sell” rating in a research note on Saturday, August 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Soligenix in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $6.00.
Soligenix Company Profile
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.
See Also
- Five stocks we like better than Soligenix
- How is Compound Interest Calculated?
- Rivian’s Chart Says Go, But Some Analysts Still Say No
- How to Calculate Inflation Rate
- e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts
- What Are Dividend Contenders? Investing in Dividend Contenders
- T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.
